سر اور گردن کا کینسر
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
کہاں جانا ہے
1 ہسپتال انڈیا میں اس ٹرائل کے لیے مریض لے رہا ہے۔
رجسٹری کی سمری (ٹیکنیکل)
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Sponsor: NATCO Pharma Ltd.
NCT05283226 on ClinicalTrials.gov
رجسٹری پر آخری اپڈیٹ 23 جنوری 2026 · ہم نے 20 اکتوبر 2026 کو پڑھا